• Usman Ali
• MOHD QAMAR
• MRS.YASHIKA UNIYAL

In the past 20 years, a large number of oral anti-cancer medications have entered the market. For instance, kinase inhibitors, such BCR-ABL and BRAF inhibitors, have significantly improved the therapy of melanoma and chronic myeloid leukaemia. A traditional way of treating cancer known as anti-angiogenic therapy tries to stop the supply of nutrients and oxygen to the tumour cells by reducing the vascular network and preventing the growth of new blood vessels. This may be the case since only a small portion of the modest increase for patients is attributable to newly discovered and recently marketed medications. Improvements could be suggested through a performance evaluation of the regulatory authorities. Drugs must be released quickly for patients who require them, but not at the price of proper information on the drugs' true benefits. Chemotherapy, Lenalidomide, Bendamustine, Plicamycin, Hexalen, elispar are medication that provide long term medication.

CANCER, TUMOR, HEXALEN, CHEMOTHERAPY, BENDAMUSTINE, LEUKOMENIA.

"MARKETING SURVEY OF ANTI CANCER DRUG", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.9, Issue 11, page no.f363-f374, November-2022, Available :http://www.jetir.org/papers/JETIR2211548.pdf

"MARKETING SURVEY OF ANTI CANCER DRUG", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.9, Issue 11, page no. ppf363-f374, November-2022, Available at : http://www.jetir.org/papers/JETIR2211548.pdf